latest news releases from the newsroom
Celltech Group plc
Celltech Group plc -- Closure of Seattle Research Facility
SLOUGH, U.K., Nov. 19, 2003 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today a reorganisation of its R&D operations designed to rebalance resources between its research and development activities. It will close its novel target discovery facility in Seattle, US at the beginning of 2004, with certain key activities being transferred to other sites. The annualised savings deriving from this closure of approximately GBP11.5 million will be reinvested in R&D, with particular focus on accelerating Celltech's early stage development pipeline, including novel anti-inflammatory treatments CDP 484, CDP 323 and CDP 146.
J Sainsbury -- video interview with CEO
LONDON, Nov. 19, 2003 (PRIMEZONE) -- J Sainsbury -- new CEO and interim results in an Indepth interview available now on http://www.cantos.com with Sir Peter Davis, Group Chief Executive.
Medivir and Hengrui Enter Discovery Collaboration to Develop Drugs for COPD
HUDDINGE, Sweden, Nov. 19, 2003 (PRIMEZONE) -- Medivir (Huddinge, Sweden) and Jiangsu Hengrui Medicine Company (Shanghai, Peoples Republic of China) have entered a discovery collaboration to jointly develop protease inhibitor drugs for COPD (Chronic Obstructive Pulmonary Disease). The collaboration, which extends over several years, will combine Medivir's protease inhibitor program in COPD, screening systems and discovery technologies with Hengrui's acknowledged expertise in medicinal chemistry. Drug products resulting from the partnership will be commercialized by Hengrui in China and by Medivir in the rest of the world.
Roche and Medivir Invest in New Virology Program and Restructure Existing HIV Collaboration
HUDDINGE, Sweden, Nov. 19, 2003 (PRIMEZONE) -- Roche and Medivir announced today a new research agreement in the area of hepatitis C (HCV) and the restructuring of their current alliance in the area of HIV. Regarding the ongoing agreement signed in April 2002, Medivir will assume responsibility for MV026048, a compound currently in development for the treatment of HIV, and Roche will provide guidance while retaining an opportunity to opt in to the program at a later date. In the new collaboration, the partners will embark on a joint research program to discover novel inhibitor compounds for the treatment of hepatitis C infections.
Trintech Group Plc
Trintech Achieves ZKA approval for PayWare OpenPay Security Design
LONDON and DALLAS, Nov. 19, 2003 (PRIMEZONE) -- Trintech Group Plc (Nasdaq:TTPA) (Prime Standard:TTP), a leading provider of transaction management and payment infrastructure solutions, today announced that it has achieved ZKA (Zentraler Kreditausschuss) approval for its OpenPay Architecture for use in the Smart 5000 PIN Pad terminal and it's new range of OEM payment security technology products. This is the first approval of its kind for a PIN Pad device using a LINUX open standard operating system. ZKA is the German regulatory body responsible for all aspects of card payments in Germany, and is widely acknowledged for setting the most stringent PIN Pad testing standards in the world.
Novartis' 2003 'R&D Day'
BASEL, Switzerland, Nov. 19, 2003 (PRIMEZONE) -- Novartis will today present its pharmaceutical pipeline to the media and financial community at our annual 'R&D Day' event in New York.